Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ Open
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN
CMAJ Open

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • RSS feeds
Getting new auth cookie, if you see this message a lot, tell someone!
Research

Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis

Tara Gomes, Andrea Mastorakos, J. Michael Paterson, Ingrid Sketris, Patricia Caetano, Simon Greaves, David Henry and for the Canadian Network for Observational Drug Effect Studies Investigators
November 22, 2017 5 (4) E800-E807; DOI: https://doi.org/10.9778/cmajo.20170104
Tara Gomes
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Mastorakos
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
HBSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Michael Paterson
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Sketris
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
PharmDMPA(HSA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Caetano
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Greaves
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Henry
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Rate of dispensing of long-acting opioids (in milligrams of morphine equivalents [MMEs] per 1000 population) in Canada, May 2008-April 2016, by province.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Rate of dispensing of immediate-release opioid dispensing (in milligrams of morphine equivalents [MMEs] per 1000 population) in Canada, May 2008-April 2016, by province.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Figure 3: Rate of dispensing of long-acting opioids (in milligrams of morphine equivalents [MMEs] per 1000 population) in Canada, May 2008-April 2016, by opioid type.

Tables

  • Figures
    • View popup
    Table 1: Characteristics of opioid formulations included in the study
    DrugMorphine conversion factorLong-acting opioid formulationsShort-acting opioid formulations
    FormulationUnit dosage rangeFormulationUnit dosage range
    Oxycodone1.71Oral5-80 mgOral2.5-20 mg
    Hydromorphone4.5Oral3-32 mgOral1-8 mg
    Morphine1Oral10-200 mgOral1-60 mg
    Fentanyl12 µg/h: 52Transdermal12-100 µg/h--
    25 µg/h: 97
    37 µg/h: 157
    50 µg/h: 202
    75 µg/h: 292
    100 µg/h: 382
    Codeine0.15Oral50-200 mgOral5-60 mg
    • View popup
    Table 2: Summary of long-acting opioid prescription patterns by province at the beginning and end of the study period
    ProvinceMay 2008-October 2008November 2015-April 2016Overall comparisons
    No. of prescriptionsNo. of prescriptions per 100 000No. of units per prescriptionNo. of MMEs per prescriptionNo. of prescriptionsNo. of prescriptions per 100 000No. of units per prescriptionNo. of MMEs per prescription% change prescription rate% change no. of MMEs per prescription
    British Columbia206 0164579533162258 498549240167219.9-47.1
    Alberta149 8003952714490221 583523658303832.5-32.3
    Saskatchewan48 198452056379268 742601653276133.1-27.2
    Manitoba50 867412359404161 860474450255315.1-36.8
    Ontario840 12463346345081 047 412754948239719.2-46.8
    Quebec412 1535147322153648 582781925113151.9-47.5
    New Brunswick41 005542756330954 297719452246232.6-25.6
    Nova Scotia38 344406074418666 800706352234774.0-43.9
    Prince Edward Island509635386732617578515766275045.8-15.7
    Newfoundland and Labrador18 830358654347332 144608446251569.6-27.6
    Average4527593638623649236237.8-35.1

    Note: MME = milligrams of morphine equivalent.

    PreviousNext
    Back to top

    In this issue

    CMAJ Open: 5 (4)
    Vol. 5, Issue 4
    21 Dec 2017
    • Table of Contents
    • Index by author

    Article tools

    Respond to this article
    Print
    Download PDF
    Article Alerts
    To sign up for email alerts or to access your current email alerts, enter your email address below:
    Email Article

    Thank you for your interest in spreading the word on CMAJ Open.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis
    (Your Name) has sent you a message from CMAJ Open
    (Your Name) thought you would like to see the CMAJ Open web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis
    Tara Gomes, Andrea Mastorakos, J. Michael Paterson, Ingrid Sketris, Patricia Caetano, Simon Greaves, David Henry, for the Canadian Network for Observational Drug Effect Studies Investigators
    Nov 2017, 5 (4) E800-E807; DOI: 10.9778/cmajo.20170104

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis
    Tara Gomes, Andrea Mastorakos, J. Michael Paterson, Ingrid Sketris, Patricia Caetano, Simon Greaves, David Henry, for the Canadian Network for Observational Drug Effect Studies Investigators
    Nov 2017, 5 (4) E800-E807; DOI: 10.9778/cmajo.20170104
    Twitter logo Facebook logo Mendeley logo
    • Tweet Widget
    • Facebook Like

    Related Articles

    • PubMed
    • Google Scholar

    Cited By...

    • Time trends and patterns in opioid prescription use following orthopaedic surgery in Ontario, Canada, from 2004/2005 to 2017/2018: a population-based study
    • The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis
    • Prescription opioid use among drivers in British Columbia, 1997-2016
    • Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada
    • Google Scholar

    Similar Articles

    Collections

    • Clinical
      • Drugs
        • Drug misuse
        • Regulation
      • Anesthesia & Analgesia
        • Pain (including opioids)

    Content

    • Current issue
    • Past issues
    • Collections

    About

    • General Information
    • Staff
    • Editorial Board
    • Advisory Panel
    • Contact Us
    • Reprints
    • Copyright and Permissions
    CMAJ Group

    Copyright 2025, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

    All editorial matter in CMAJ OPEN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

    To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

    CMA Civility, Accessibility, Privacy

     

     

    Powered by HighWire